Research Lab Results
-
Sydney Dy Lab
The Sydney Dy Lab has conducted extensive research on quality of care, patient safety and decision-making, with a focus on patients with cancer and other serious and terminal diseases. Our team seeks to improve health systems and services to optimize the use of technology and medication, particularly in end-of-life health care policy. Our research approach includes primary and quantitative data collection, quality measurement improvement, systematic literature reviews and analysis of secondary database. -
Jonathan Weiner Lab
The Jonathan Weiner Lab researches the impact of electronic health records (EHRs), e-health and other health information technology (HIT) on populations, integrated delivery systems and public health agencies.Principal Investigator
-
John Matthew Austin Lab
Research in the John Matthew Austin Lab explores health care performance measures, with a goal of improving patient care by enabling healthcare providers to view data about their performance, track patient outcomes and comply with best care practices. Our lab is currently working to develop performance measures for the ICU part, and we are part of The Leapfrog Group, an annual survey of U.S. hospitals that compares hospital performance on national measures of safety, quality and efficiency. Our research also explores the use of scientifically sound decision-support tools for guiding improvements in healthcare delivery systems. -
Cheryl Dennison Himmelfarb Lab
Research in the Cheryl Dennison Lab aims to improve cardiovascular care for high-risk groups through multidisciplinary and health information technology-based methods. Our studies focus on reducing system and provider obstacles to implementing cardiovascular guidelines in various health care environments. Additional research interests include chronic illness management, quality of care, interdisciplinary teamwork and provider behavior.Lab WebsitePrincipal Investigator
-
Pali Shah Lab
Research in the Pali Shah Lab focuses on lung transplants. Specifically, we’re interested in chronic rejection and quality and safety as they relate to lung transplants.